IN2012DN02763A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN02763A IN2012DN02763A IN2763DEN2012A IN2012DN02763A IN 2012DN02763 A IN2012DN02763 A IN 2012DN02763A IN 2763DEN2012 A IN2763DEN2012 A IN 2763DEN2012A IN 2012DN02763 A IN2012DN02763 A IN 2012DN02763A
- Authority
- IN
- India
- Prior art keywords
- disease
- kinase activity
- lrrk2 kinase
- larly
- particu
- Prior art date
Links
- 102000009784 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Human genes 0.000 abstract 2
- 108010020246 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Proteins 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24655009P | 2009-09-29 | 2009-09-29 | |
| CN2010001334 | 2010-09-02 | ||
| PCT/CN2010/001501 WO2011038572A1 (en) | 2009-09-29 | 2010-09-27 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN02763A true IN2012DN02763A (enExample) | 2015-09-18 |
Family
ID=43825509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2763DEN2012 IN2012DN02763A (enExample) | 2009-09-29 | 2010-09-27 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8778939B2 (enExample) |
| EP (1) | EP2483254B1 (enExample) |
| JP (1) | JP5752691B2 (enExample) |
| KR (1) | KR20120081609A (enExample) |
| AU (1) | AU2010302842B2 (enExample) |
| BR (1) | BR112012006859A2 (enExample) |
| CA (1) | CA2775753A1 (enExample) |
| EA (1) | EA021437B1 (enExample) |
| ES (1) | ES2512727T3 (enExample) |
| IL (1) | IL218674A (enExample) |
| IN (1) | IN2012DN02763A (enExample) |
| MX (1) | MX2012003778A (enExample) |
| SG (1) | SG179120A1 (enExample) |
| WO (1) | WO2011038572A1 (enExample) |
| ZA (1) | ZA201201877B (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011260323A1 (en) | 2010-06-04 | 2012-11-15 | F. Hoffmann-La Roche Ag | Aminopyrimidine derivatives as LRRK2 modulators |
| AR082827A1 (es) * | 2010-09-02 | 2013-01-09 | Glaxo Group Ltd | Compuestos de aril-metiloxi-benzamida, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento util para el tratamiento o la profilaxis de la enfermedad de parkinson |
| CA3017869C (en) | 2010-11-10 | 2021-07-27 | Genentech, Inc. | Pyrazole aminopyrimidine derivatives as lrrk2 modulators |
| ES2660996T3 (es) * | 2011-05-03 | 2018-03-27 | PRCL Research Inc. | Compuestos para la inflamación y usos relacionados con el sistema inmunitario |
| CN103917525B (zh) * | 2011-05-23 | 2016-08-17 | 依兰制药公司 | Lrrk2激酶活性的抑制剂 |
| US9096609B2 (en) * | 2011-09-30 | 2015-08-04 | Ipsen Pharma S.A.S. | Macrocyclic LRRK2 kinase inhibitors |
| MX348920B (es) | 2011-11-29 | 2017-07-04 | Genentech Inc | Derivados de 2-(fenil o pirid-3-il)aminopirimidina como moduladores de proteina cinasa 2 de repeticion rica en leucina (lrrk2) para el tratamiento de la enfermedad de parkinson. |
| KR102012057B1 (ko) | 2011-11-29 | 2019-08-19 | 제넨테크, 인크. | Lrrk2 조절제로서 아미노피리미딘 유도체 |
| AR089182A1 (es) | 2011-11-29 | 2014-08-06 | Hoffmann La Roche | Derivados de aminopirimidina como moduladores de lrrk2 |
| BR112014011850B1 (pt) | 2011-11-29 | 2022-01-11 | Genentech, Inc | Derivados de aminopirimidina, seus usos, e composição farmacêutica |
| RU2650641C2 (ru) | 2011-11-30 | 2018-04-16 | Дженентек, Инк. | Фтор-18 и углерод-11 меченые радиолиганды для томографии с позитронной эмиссией (рет), визуализирующей lrrk2 |
| CA2878054C (en) | 2012-06-29 | 2018-09-11 | Pfizer Inc. | Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors |
| EP3539965B1 (en) * | 2013-12-09 | 2021-01-20 | Unichem Laboratories Limited | An improved process for the preparation of (3r,4r)-(1-benzyl-4-methylpiperidin-3-yl)-methylamine |
| WO2015092592A1 (en) | 2013-12-17 | 2015-06-25 | Pfizer Inc. | Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors |
| US9815841B2 (en) | 2014-01-29 | 2017-11-14 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
| CN105940004B (zh) * | 2014-01-29 | 2018-02-02 | 葛兰素史密斯克莱知识产权发展有限公司 | 化合物 |
| CN106604913A (zh) | 2014-03-31 | 2017-04-26 | 纽约哥伦比亚大学理事会 | 组蛋白乙酰基转移酶激活剂及其用途 |
| WO2015176010A1 (en) | 2014-05-15 | 2015-11-19 | The United States Of America, As Represented By The Secretary, Departmentof Health & Human Services | Treatment or prevention of an intestinal disease or disorder |
| TR201909606T4 (tr) | 2014-07-31 | 2019-07-22 | Basf Se | Pi̇razollari hazirlamak i̇çi̇n i̇şlem |
| CN105348182B (zh) * | 2014-08-24 | 2018-04-13 | 复旦大学 | 2‑烷氧基苯甲酰芳胺类化合物及其药物用途 |
| CA2960777A1 (en) | 2014-09-17 | 2016-03-24 | Oncodesign S.A. | Macrocyclic lrrk2 kinase inhibitors |
| AU2015362790A1 (en) | 2014-12-16 | 2017-07-20 | Axovant Sciences Gmbh | Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors |
| BR112017023935B1 (pt) | 2015-05-11 | 2020-07-07 | Basf Se | processo para a preparação de um composto |
| DK3294725T3 (da) * | 2015-05-11 | 2021-07-26 | Basf Se | Fremgangsmåde til fremstilling af 4-aminopyridaziner |
| MX2017016231A (es) | 2015-06-10 | 2018-11-29 | Axovant Sciences Gmbh | Compuestos de aminobencisoxazol como agonistas de receptores a7-nicotínicos de acetilcolina. |
| EP3334740A4 (en) | 2015-08-12 | 2019-02-06 | Axovant Sciences GmbH | GEMINAL SUBSTITUTED AMINOBENZISOXAZOLE COMPOUNDS AS AGONISTS OF ALPHA 7-NICOTINIC ACETYLCHOLINE RECEPTORS |
| AU2016322813B2 (en) | 2015-09-14 | 2021-04-01 | Pfizer Inc. | Novel imidazo (4,5-c) quinoline and imidazo (4,5-c)(1,5) naphthyridine derivatives as LRRK2 inhibitors |
| US20190297887A1 (en) | 2016-07-12 | 2019-10-03 | Bayer Cropscience Aktiengesellschaft | Bicyclic compounds as pesticides |
| WO2018082964A1 (en) | 2016-11-04 | 2018-05-11 | Basf Se | Process for the production of pyridazinyl-amides in a one-pot synthesis |
| CN110446700A (zh) * | 2017-01-25 | 2019-11-12 | 葛兰素史密斯克莱知识产权发展有限公司 | 化合物 |
| JP6728503B2 (ja) | 2017-02-24 | 2020-07-22 | テグ−キョンプク メディカル イノベーション ファウンデーション | 血液脳関門を通過することができる化合物を有効成分として含有する脳腫瘍の予防または治療用薬学的組成物 |
| KR101990739B1 (ko) | 2018-07-24 | 2019-06-19 | 재단법인 대구경북첨단의료산업진흥재단 | 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물 |
| KR101990738B1 (ko) | 2018-07-24 | 2019-06-19 | 재단법인 대구경북첨단의료산업진흥재단 | 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물 |
| KR101992059B1 (ko) | 2018-08-23 | 2019-06-21 | 재단법인 대구경북첨단의료산업진흥재단 | 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물 |
| US20220396575A1 (en) | 2019-08-30 | 2022-12-15 | Tsd Life Sciences Co., Ltd. | Imidazopyridine derivative and pharmaceutical composition comprising same as active ingredient |
| WO2023076404A1 (en) | 2021-10-27 | 2023-05-04 | Aria Pharmaceuticals, Inc. | Methods for treating systemic lupus erythematosus |
| JP2025034990A (ja) * | 2023-08-31 | 2025-03-13 | 東京応化工業株式会社 | レジスト組成物、レジストパターン形成方法、化合物、及び酸拡散制御剤 |
| CN119432181B (zh) * | 2024-11-28 | 2025-07-15 | 佛山市德堡建材有限公司 | 一种环保型聚合物水泥防水涂料及其制备方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5449691A (en) * | 1991-12-31 | 1995-09-12 | Sterling Winthrop Inc. | 3,4-disubstituted anilines-immunomodulating agents |
| WO1997008135A1 (de) * | 1995-08-30 | 1997-03-06 | Bayer Aktiengesellschaft | Acylaminosalicylsäureamide und ihre verwendung als schädlingsbekämpfungsmittel |
| CA2288330C (en) | 1997-05-07 | 2014-02-11 | University Of Pittsburgh | Benzoyl amino acid derivatives useful as inhibitors of protein isoprenyl tranferases |
| JP2002512633A (ja) | 1997-06-26 | 2002-04-23 | イーライ・リリー・アンド・カンパニー | 抗血栓剤 |
| CN1301154A (zh) | 1998-03-26 | 2001-06-27 | 日本烟草产业株式会社 | 酰胺衍生物和nociceptin拮抗剂 |
| ES2215893T3 (es) | 2000-03-17 | 2004-10-16 | Bristol-Myers Squibb Pharma Company | Derivados de beta-aminoacidos como inhibidores de metaloproteasas de matriz y tnf-alfa. |
| GB0023983D0 (en) | 2000-09-29 | 2000-11-15 | Prolifix Ltd | Therapeutic compounds |
| DE10159453A1 (de) | 2001-12-04 | 2003-06-18 | Merck Patent Gmbh | Verwendung von 1-Phenyl-oxazolidin-2-on-Verbindungen als Protease |
| CA2482341A1 (en) | 2002-04-09 | 2003-10-23 | 7Tm Pharma A/S | Novel methoxybenzamide compounds for use in mch receptor related disorders |
| WO2003087044A2 (en) | 2002-04-09 | 2003-10-23 | 7Tm Pharma A/S | Novel carboxamide compounds for use in mch receptor related disorders |
| MXPA05011536A (es) | 2003-04-30 | 2006-01-23 | Inst For Pharm Discovery Inc | Acidos carboxilicos substituidos con fenilo como inhibidores de la proteina tirosina fosfatasa-1b. |
| WO2004099127A1 (en) | 2003-05-07 | 2004-11-18 | Novo Nordisk A/S | Novel compounds as kinase inhibitors |
| WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
| US7550485B2 (en) | 2003-10-14 | 2009-06-23 | Wyeth | Substituted N-heterocycle derivatives and methods of their use |
| WO2005073210A1 (ja) * | 2004-01-28 | 2005-08-11 | Kissei Pharmaceutical Co., Ltd. | 新規なベンゾフラン誘導体、それを含有する医薬組成物およびそれらの用途 |
| TW200606133A (en) | 2004-06-30 | 2006-02-16 | Sankyo Co | Substituted benzene compounds |
| US7671077B2 (en) | 2004-07-19 | 2010-03-02 | Leu-Fen Hou Lin | Neuroprotective small organic molecules, compositions and uses related thereto |
| US20060276496A1 (en) | 2005-03-17 | 2006-12-07 | Boehringer Ingelheim Pharmaceuticals, Inc. | Anti-Cytokine Heterocyclic Compounds |
| BRPI0615948A2 (pt) * | 2005-09-07 | 2011-05-31 | Plexxikon Inc | composto ativo de ppar, sua composição, seu kit e seu uso |
| JP2007176799A (ja) | 2005-12-27 | 2007-07-12 | Sankyo Co Ltd | 置換ベンゼン化合物を含有する医薬 |
| CN101395158A (zh) * | 2006-03-07 | 2009-03-25 | 百时美施贵宝公司 | 可作为激酶抑制剂的吡咯并三嗪苯胺前体药物化合物 |
| EP2019824A2 (en) | 2006-04-28 | 2009-02-04 | Transtech Pharma, Inc. | Benzamide glucokinase activators |
| JP5069752B2 (ja) * | 2006-12-15 | 2012-11-07 | グラクソ グループ リミテッド | Ｅｐ４受容体アゴニストとしてのベンズアミド誘導体 |
| WO2009030270A1 (en) | 2007-09-03 | 2009-03-12 | Novartis Ag | Dihydroindole derivatives useful in parkinson's disease |
| GB0722680D0 (en) | 2007-11-19 | 2007-12-27 | Topotarget As | Therapeutic compounds and their use |
| WO2010048559A2 (en) | 2008-10-24 | 2010-04-29 | Calcimedica Inc. | Phenylpyrazole inhibitors of store operated calcium release |
-
2010
- 2010-09-27 EP EP10819801.1A patent/EP2483254B1/en active Active
- 2010-09-27 MX MX2012003778A patent/MX2012003778A/es active IP Right Grant
- 2010-09-27 WO PCT/CN2010/001501 patent/WO2011038572A1/en not_active Ceased
- 2010-09-27 CA CA2775753A patent/CA2775753A1/en not_active Abandoned
- 2010-09-27 KR KR1020127010852A patent/KR20120081609A/ko not_active Abandoned
- 2010-09-27 US US13/498,975 patent/US8778939B2/en not_active Expired - Fee Related
- 2010-09-27 ES ES10819801.1T patent/ES2512727T3/es active Active
- 2010-09-27 BR BR112012006859A patent/BR112012006859A2/pt not_active IP Right Cessation
- 2010-09-27 AU AU2010302842A patent/AU2010302842B2/en not_active Ceased
- 2010-09-27 EA EA201270480A patent/EA021437B1/ru not_active IP Right Cessation
- 2010-09-27 IN IN2763DEN2012 patent/IN2012DN02763A/en unknown
- 2010-09-27 JP JP2012531212A patent/JP5752691B2/ja not_active Expired - Fee Related
- 2010-09-27 SG SG2012017760A patent/SG179120A1/en unknown
-
2012
- 2012-03-14 ZA ZA2012/01877A patent/ZA201201877B/en unknown
- 2012-03-15 IL IL218674A patent/IL218674A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP2483254A1 (en) | 2012-08-08 |
| US20120184553A1 (en) | 2012-07-19 |
| AU2010302842A1 (en) | 2012-04-12 |
| EA021437B1 (ru) | 2015-06-30 |
| BR112012006859A2 (pt) | 2019-09-24 |
| EP2483254B1 (en) | 2014-08-13 |
| IL218674A (en) | 2015-11-30 |
| EP2483254A4 (en) | 2013-02-27 |
| MX2012003778A (es) | 2012-06-01 |
| WO2011038572A1 (en) | 2011-04-07 |
| SG179120A1 (en) | 2012-05-30 |
| ES2512727T3 (es) | 2014-10-24 |
| US8778939B2 (en) | 2014-07-15 |
| JP5752691B2 (ja) | 2015-07-22 |
| ZA201201877B (en) | 2012-11-28 |
| JP2013505969A (ja) | 2013-02-21 |
| CA2775753A1 (en) | 2011-04-07 |
| AU2010302842B2 (en) | 2014-05-08 |
| EA201270480A1 (ru) | 2013-08-30 |
| IL218674A0 (en) | 2012-05-31 |
| KR20120081609A (ko) | 2012-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN02763A (enExample) | ||
| MY176944A (en) | Substituted pyrimidines for the treatment of diseases such as cancer | |
| MX2009000333A (es) | Pirrilopirimidinas para composiciones farmaceuticas. | |
| TW200800968A (en) | Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs | |
| AU2012258977A8 (en) | Inhibitors of LRRK2 kinase activity | |
| MX2012007273A (es) | Pteridinonas como inhibidores de la quinasa tipo polo. | |
| WO2009127642A3 (en) | Use of lrrk2 inhibitors for neurodegenerative diseases | |
| BR112012006858A2 (pt) | metodo de aperfeicoamento do desempenho de impressao em placas de impressao flexografica | |
| MX2011011661A (es) | Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750. | |
| MX342177B (es) | Inhibidores de cinasa 2 de repeticion rica en leucina (lrrk2) macrociclica. | |
| UA94944C2 (ru) | 2,4-диаминопиримидины как ингибиторы киназ, которые принимают участие в регуляции клеточного цикла | |
| MX340807B (es) | Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central. | |
| HK1215579A1 (zh) | 被取代的2，3-二氫苯並呋喃基化合物和其用途 | |
| MX2009010407A (es) | Derivados fluorados de deferiprona. | |
| TNSN07383A1 (en) | 1-h-quinazoline-2,4-diones and their use as ampa-receptor ligands | |
| AP2011005978A0 (en) | 2, 4 diaminopyrimidines for the treatment of diseases characterised by excessive or abnormal cell proliferation. | |
| MY150931A (en) | Substituted oxazolidinones and their use | |
| MX2010009837A (es) | Tiazolil-dihidro-indazoles. | |
| TN2011000531A1 (en) | 5- alkynyl - pyridines | |
| TW200640911A (en) | Novel, long acting betamimetics for the treatment of respiratory diseases | |
| TW200726763A (en) | Novel compound | |
| WO2011008675A3 (en) | Catecholamine compounds, compositions, and formulations, and methods of using the same | |
| NZ609924A (en) | Porphyrin treatment of neurodegenerative diseases | |
| WO2009151495A3 (en) | Oxazole compounds, compositions and methods of use | |
| TN2012000370A1 (en) | 5-alkynyl pyrimidines and their use as kinase inhibitors |